Selecta Biosciences, Inc. announced the appointment of Nishan de Silva, M.D. to its Board of Directors. Dr. de Silva will provide strategic guidance and operational insights as Selecta continues to advance its clinical pipeline. He brings over 20 years of experience in biotechnology operations, biopharmaceutical venture capital and healthcare management consulting. He is currently Chief Executive Officer and Director of AFYX Therapeutics, a private venture-backed biotechnology company focusing on addressing unmet needs in mucosal diseases.